A comparison of phosphate bone-scanning agents in normal subjects and patients with malignant disease
| Autor: | D. L. Citrin, L. H. Blumgart, J. B. Tuohy, R. G. Bessent, S. T. Elms, W.R. Greig, E. McGinlay |
|---|---|
| Rok vydání: | 1975 |
| Předmět: |
Male
Organophosphonates Skeletal scanning Bone Neoplasms Radiation Dosage Pyrophosphate Whole-Body Counting Malignant disease Bone and Bones Phosphates chemistry.chemical_compound Humans Radiology Nuclear Medicine and imaging Neoplasm Metastasis Radionuclide Imaging business.industry Polyphosphate Radiochemistry Technetium General Medicine Phosphate Diphosphates Bone scanning chemistry Nuclear medicine business |
| Zdroj: | The British journal of radiology. 48(566) |
| ISSN: | 0007-1285 |
| Popis: | None of the established bone-scanning compounds 85Sr, 87Srm nor 18F is entirely satisfactory and because of this the place of skeletal scanning is not clearly defined. 18F is the most effective of the available bone-scanning compounds but its 100 minute half-life makes distribution difficult and restricts its use in Britain to the Greater London Area. There has recently been considerable interest in certain compounds of phosphate which show great promise as bone scanning agents (Subramanian et al., 1972; Yano et al., 1973; Hosain, 1973; Citrin et al., 1974). The phosphate compounds polyphosphate, pyrophosphate and ethane hydroxy diphosphonate, are readily labelled with 99Tcm in the presence of the reducing agent stannous chloride. 99Tcm is one of the standard isotopes used in nuclear medicine. Its physical characteristics are ideal and it is produced from a simple generator on site. If Tc-labelled phosphates are shown to be effective and safe then bone scanning will be routinely available in hospitals wit... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|